CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

(2016) Michael L Wang et al.   LANCET ONCOLOGY

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

(2015) Michael Doubek et al.   AMERICAN JOURNAL OF HEMATOLOGY

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

(2015) J. C. Byrd et al.   BLOOD

Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial

(2015) Jennifer R. Brown et al.   BLOOD

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

(2015) P. R. Hagner et al.   BLOOD

A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia

(2015) S. M. O'Brien et al.   BLOOD

The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

(2015) Beth A. Christian et al.   BRITISH JOURNAL OF HAEMATOLOGY

Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas

(2015) E. A. Chong et al.   CLINICAL CANCER RESEARCH

A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma

(2015) R. Chen et al.   HAEMATOLOGICA

A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR

(2015) Jing Zeng et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study

(2015) Emilio Iannitto et al.   LEUKEMIA & LYMPHOMA

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells

(2015) Emily C Piccione et al.   mAbs

Production of an active anti-CD20-hIL-2 immunocytokine in Nicotiana benthamiana

(2015) Carla Marusic et al.   PLANT BIOTECHNOLOGY JOURNAL

Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

(2015) Liping L. Sun et al.   Science Translational Medicine

A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma

(2015) R. Chen et al.   HAEMATOLOGICA

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study

(2015) Chan Yoon Cheah et al.   Lancet Haematology

Abstract 1108: B-cell lymphoma-derived exosomes are reservoirs of inhibitors of apoptosis

(2015) Heather R. Ferguson Bennit et al.   CANCER RESEARCH

99mTc carbonyl DTPA–Rituximab: Preparation and preliminary bioevaluation

(2014) Usha Pandey et al.   APPLIED RADIATION AND ISOTOPES

Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53

(2014) J.-F. Fecteau et al.   BLOOD

Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias through MLL-AF4

(2014) Han Liu et al.   CANCER CELL

Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients

(2014) Claire Fabre et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Abstract LB-140: Combined epigenetic and immunotherapy produces dramatic responses in 100% of newly diagnosed mantle cell lymphoma patients.

(2014) Zainul Hasanali et al.   CANCER RESEARCH

A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics

(2014) Carla Casulo et al.   CLINICAL IMMUNOLOGY

Expression of B-Cell Surface Antigens in Subpopulations of Exosomes Released From B-Cell Lymphoma Cells

(2014) Morten P. Oksvold et al.   CLINICAL THERAPEUTICS

Development trends for generation of single-chain antibody fragments

(2014) Safar Farajnia et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface

(2014) L. Al-Zoobi et al.   INTERNATIONAL IMMUNOLOGY

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

(2014) Nathan H Fowler et al.   LANCET ONCOLOGY

Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma

(2014) Kristen N. Ganjoo et al.   LEUKEMIA & LYMPHOMA

Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse

(2014) Marie Vincent et al.   mAbs

Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death

(2014) Kim L Brunekreeft et al.   Molecular Cancer

Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice

(2014) Y. Chu et al.   Cancer Immunology Research

Pancytopenia following vivax malaria in a CLL patient

(2013) P. Sharma et al.   BLOOD

Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFP

(2013) L. Zhao et al.   BLOOD

Isolated plasmacytoma involving the brain parenchyma and cerebral spinal fluid

(2013) Q. Huang   BLOOD

Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts

(2013) R. Voltan et al.   CLINICAL CANCER RESEARCH

Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin

(2013) Zhao Hui Li et al.   INVESTIGATIONAL NEW DRUGS

Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study

(2013) Gilles A. Salles et al.   JOURNAL OF CLINICAL ONCOLOGY

Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study

(2013) Franck Andre Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties

(2013) S. Rafiq et al.   JOURNAL OF IMMUNOLOGY

Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma

(2013) Zi-Zhen Xu et al.   LEUKEMIA & LYMPHOMA

Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia

(2013) Deborah M. Stephens et al.   LEUKEMIA RESEARCH

Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule

(2013) Clarissa G. Jakob et al.   mAbs

Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma

(2013) Lihua E. Budde et al.   PLoS One

High levels of reactive oxygen species in gold nanoparticle-targeted cancer cells following femtosecond pulse irradiation

(2013) Limor Minai et al.   Scientific Reports

Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others

(2013) Hideaki Kobayashi et al.   Cancer Medicine

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

(2013) Laurent Boissel et al.   OncoImmunology

Anti-CD20 multivalent HPMA copolymer-Fab′ conjugates for the direct induction of apoptosis

(2012) Te-Wei Chu et al.   BIOMATERIALS

Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia

(2012) B. Yu et al.   BLOOD

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

(2012) P. Gupta et al.   BLOOD

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

(2012) B. G. Till et al.   BLOOD

Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression

(2012) Ling-Hua Zhang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination within-situdendritic cell vaccination in advanced lymphoma

(2012) S. Manzur et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders

(2012) J. M. Timmerman et al.   CLINICAL CANCER RESEARCH

Combined Administration of Rituximab and ON 013105 Induces Apoptosis in Mantle Cell Lymphoma Cells and Reduces Tumor Burden in a Mouse Model of Mantle Cell Lymphoma

(2012) A. Prasad et al.   CLINICAL CANCER RESEARCH

Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma

(2012) Andres Forero-Torres et al.   CLINICAL CANCER RESEARCH

Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma

(2012) D. Mahadevan et al.   CLINICAL CANCER RESEARCH

Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity

(2012) Magdalena Winiarska et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer CellsIn Situ

(2012) Michaela R. Reagan et al.   Journal of Breast Cancer

Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

(2012) Christian Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Human Umbilical Cord Mesenchymal Stem Cells as Vehicles of CD20-Specific TRAIL Fusion Protein Delivery: A Double-Target Therapy against Non-Hodgkin’s Lymphoma

(2012) Cihui Yan et al.   MOLECULAR PHARMACEUTICS

Proteomic Analysis of S-Acylated Proteins in Human B Cells Reveals Palmitoylation of the Immune Regulators CD20 and CD23

(2012) Corinne Ivaldi et al.   PLoS One

CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101

(2011) M. Jak et al.   BLOOD

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

(2011) G. Niederfellner et al.   BLOOD

90 Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma

(2011) K E Abou-Nassar et al.   BONE MARROW TRANSPLANTATION

The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone

(2011) Joseph M. Tuscano et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3

(2011) T. Aung et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

(2010) F. Morschhauser et al.   ANNALS OF ONCOLOGY

Proteolytic pathways involved in modulation of CD20 levels

(2010) Magdalena Winiarska et al.   Autophagy

Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

(2010) Michael C. Jensen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance

(2010) C. Henry et al.   BLOOD

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

(2010) R. Abes et al.   BLOOD

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

A Bispecific Antibody-IFN 2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells

(2010) E. A. Rossi et al.   CANCER RESEARCH

Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study

(2010) Julie E. Chang et al.   Clinical Lymphoma Myeloma & Leukemia

Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma

(2010) G. O. Negrea et al.   HAEMATOLOGICA

BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties

(2010) Nishida   INTERNATIONAL JOURNAL OF ONCOLOGY

Reply to S. Kilickap et al

(2010) Ahsun Riaz et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

(2010) Jia Ruan et al.   JOURNAL OF CLINICAL ONCOLOGY

Understanding and circumventing resistance to anticancer monoclonal antibodies

(2010) Lina Reslan et al.   mAbs

Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab

(2009) R. Seki et al.   ANNALS OF ONCOLOGY

CD20-targeted tetrameric interferon- , a novel and potent immunocytokine for the therapy of B-cell lymphomas

(2009) E. A. Rossi et al.   BLOOD

CD20 deficiency in humans results in impaired T cell–independent antibody responses

(2009) Taco W. Kuijpers et al.   JOURNAL OF CLINICAL INVESTIGATION

Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results

(2009) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

(2008) D. M. Goldenberg et al.   BLOOD

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

(2008) B. G. Till et al.   BLOOD

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

(2008) C. Schliemann et al.   BLOOD

Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody

(2008) R. M. Sharkey et al.   CANCER RESEARCH

Superior Activity of Fusion Protein scFvRit:sFasL over Cotreatment with Rituximab and Fas Agonists

(2008) E. Bremer et al.   CANCER RESEARCH

Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics

(2008) E. A. Rossi et al.   CANCER RESEARCH

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

(2008) E. Racila et al.   CLINICAL CANCER RESEARCH

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

(2008) L. Wu et al.   CLINICAL CANCER RESEARCH

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

(2008) M. S. Czuczman et al.   CLINICAL CANCER RESEARCH

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti‐CD20 × anti‐CD3), mediates efficient killing of B‐cell lymphoma cells even with very low CD20 expression levels

(2008) Michael Stanglmaier et al.   INTERNATIONAL JOURNAL OF CANCER

Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)

(2008) Avi Ashkenazi et al.   JOURNAL OF CLINICAL ONCOLOGY

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma

(2008) T Stühmer et al.   LEUKEMIA